Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs JPMorgan Ultra Short Income ETF (JPST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs JPMorgan Ultra Short Income ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B), while JPMorgan Ultra Short Income ETF trades at $50.47. The key difference: JPMorgan Ultra Short Income ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | JPST | |
|---|---|---|
Market Cap | $29.60B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $491.22 | $50.78 |
52-Week Low | $205.48 | $50.40 |
Enterprise Value | $27.56B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
JPST (JPMorgan Ultra-Short Income ETF) trades at $50.46, showing minimal daily movement with a 0.04% gain. The technical outlook is bearish based on moving averages, though oscillators are neutral. Recent institutional filings show growing interest, with Financial Management Professionals increasing their stake by 4.7% in Q2 2026. The fund provides regular dividend distributions, with recent payments of $0.17 per share.
As an ultra-short income ETF, JPST offers stability and income generation in a rising rate environment. The fund's conservative positioning appeals to risk-averse investors seeking cash alternatives. Key risks include interest rate sensitivity and inflationary pressures that could impact short-term bond yields. Institutional accumulation suggests confidence in the fund's strategic positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About JPMorgan Ultra Short Income ETF
JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.
Read more on JPST →
